Ajanta Pharma Denies Involvement in Rumoured Restaurant Brands Asia Acquisition

An update from Ajanta Pharma Limited ( (IN:AJANTPHARM) ) is now available.

Ajanta Pharma has issued a formal clarification denying media reports that it plans to raise Rs 2,000 crore to acquire Restaurant Brands Asia and diversify into the quick-service restaurant sector. The company stated that the reference to Ajanta Pharma in a recent Economic Times article is factually incorrect and that neither the company nor its management is involved in any such transaction.

According to the clarification, a section of the promoter group that manages and controls Lenexis Foodworks Pvt. Ltd. is independently pursuing the acquisition of Restaurant Brands Asia, in a transaction separate from Ajanta Pharma. By distancing itself from the reported deal, Ajanta Pharma aims to quell market rumours, prevent investor misperception about its strategic direction, and reaffirm that its core operations remain focused on pharmaceuticals rather than diversification into food services.

More about Ajanta Pharma Limited

Ajanta Pharma Limited is an Indian pharmaceutical company based in Mumbai that develops, manufactures, and markets branded generics and specialty medicines. It operates in both domestic and international markets, supplying a range of formulations across therapeutic segments and focusing on regulated as well as emerging markets.

Average Trading Volume: 7,630

Technical Sentiment Signal: Strong Buy

Current Market Cap: 356.4B INR

Learn more about AJANTPHARM stock on TipRanks’ Stock Analysis page.